Literature DB >> 21224235

Functional sympatholysis is impaired in hypertensive humans.

Wanpen Vongpatanasin1, Zhongyun Wang, Debbie Arbique, Gary Arbique, Beverley Adams-Huet, Jere H Mitchell, Ronald G Victor, Gail D Thomas.   

Abstract

In healthy individuals, sympathetic vasoconstriction is markedly blunted in exercising muscles to optimize blood flow to the metabolically active muscle fibres. This protective mechanism, termed functional sympatholysis, is impaired in rat models of angiotensin-dependent hypertension. However, the relevance of these findings to human hypertension is unknown. Therefore, in 13 hypertensive and 17 normotensive subjects we measured muscle oxygenation and forearm blood flow (FBF) responses to reflex increases in sympathetic nerve activity (SNA) evoked by lower body negative pressure (LBNP) at rest and during moderate-intensity rhythmic handgrip exercise. In the normotensives, LBNP caused decreases in oxygenation and FBF (−16 ± 2% and −23 ± 4%, respectively) in resting forearm but not in exercising forearm (−1 ± 2% and −1 ± 3%, respectively; P < 0.05 vs. rest). In the hypertensives, LBNP evoked decreases in oxygenation and FBF that were similar in the resting and exercising forearm (−14 ± 2% vs. −12 ± 2% and −20 ± 3% vs. −13 ± 2%, respectively; P > 0.05), indicating impaired functional sympatholysis. In the hypertensives, SNA was unexpectedly increased by 54 ± 11% during handgrip alone. However, when SNA was experimentally increased during exercise in the normotensives, sympatholysis was unaffected. Treatment for 4 weeks with the angiotensin receptor blocker irbesartan, but not with the thiazide-type diuretic chlorthalidone, restored sympatholysis in the hypertensives. These data provide the first evidence that functional sympatholysis is impaired in hypertensive humans by a mechanism that appears to involve an angiotensin-dependent increase in sympathetic vasoconstriction in the exercising muscles.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21224235      PMCID: PMC3060597          DOI: 10.1113/jphysiol.2010.203026

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  43 in total

1.  Abnormal muscle metaboreflex control of sympathetic activity in never-treated hypertensive subjects.

Authors:  Maria Urbana P B Rondon; Mateus C Laterza; Luciana D N J de Matos; Ivani C Trombetta; Ana Maria W Braga; Fabiana Roveda; Maria Janieire N N Alves; Eduardo M Krieger; Carlos Eduardo Negrão
Journal:  Am J Hypertens       Date:  2006-09       Impact factor: 2.689

2.  Reactive oxygen species impair sympathetic vasoregulation in skeletal muscle in angiotensin II-dependent hypertension.

Authors:  Weiying Zhao; Scott A Swanson; Jianfeng Ye; Xilong Li; John M Shelton; Weiguo Zhang; Gail D Thomas
Journal:  Hypertension       Date:  2006-08-28       Impact factor: 10.190

3.  Persistent sympathetic activation during chronic antihypertensive therapy: a potential mechanism for long term morbidity?

Authors:  Qi Fu; Rong Zhang; Sarah Witkowski; Armin Arbab-Zadeh; Anand Prasad; Kazunobu Okazaki; Benjamin D Levine
Journal:  Hypertension       Date:  2005-02-28       Impact factor: 10.190

4.  Exercise pressor reflex function is altered in spontaneously hypertensive rats.

Authors:  Scott A Smith; Maurice A Williams; Anna K Leal; Jere H Mitchell; Mary G Garry
Journal:  J Physiol       Date:  2006-10-05       Impact factor: 5.182

5.  Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension.

Authors:  Henry Krum; Elisabeth Lambert; Emma Windebank; Duncan J Campbell; Murray Esler
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-11-11       Impact factor: 4.733

Review 6.  The cardiovascular continuum and renin-angiotensin-aldosterone system blockade.

Authors:  Victor Dzau
Journal:  J Hypertens Suppl       Date:  2005-04

7.  Differential sympathetic neural control of oxygenation in resting and exercising human skeletal muscle.

Authors:  J Hansen; G D Thomas; S A Harris; W J Parsons; R G Victor
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

8.  Impaired modulation of sympathetic alpha-adrenergic vasoconstriction in contracting forearm muscle of ageing men.

Authors:  Frank A Dinenno; Shizue Masuki; Michael J Joyner
Journal:  J Physiol       Date:  2005-06-09       Impact factor: 5.182

9.  Augmented sympathetic vasoconstriction in exercising forearms of postmenopausal women is reversed by oestrogen therapy.

Authors:  Paul J Fadel; Zhongyun Wang; Hitoshi Watanabe; Debbie Arbique; Wanpen Vongpatanasin; Gail D Thomas
Journal:  J Physiol       Date:  2004-10-21       Impact factor: 5.182

Review 10.  Impaired exercise tolerance in hypertensive patients.

Authors:  P O Lim; R J MacFadyen; P B Clarkson; T M MacDonald
Journal:  Ann Intern Med       Date:  1996-01-01       Impact factor: 25.391

View more
  58 in total

1.  Role of nitric oxide and prostanoids in the regulation of leg blood flow and blood pressure in humans with essential hypertension: effect of high-intensity aerobic training.

Authors:  Michael Nyberg; Lasse G Jensen; Pia Thaning; Ylva Hellsten; Stefan P Mortensen
Journal:  J Physiol       Date:  2012-01-23       Impact factor: 5.182

Review 2.  Regulation of increased blood flow (hyperemia) to muscles during exercise: a hierarchy of competing physiological needs.

Authors:  Michael J Joyner; Darren P Casey
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

3.  The influence of resting blood pressure on muscle strength in healthy adults.

Authors:  Adam R Blanchard; Beth A Taylor; Paul D Thompson; Lindsey K Lepley; C M White; Lauren M Corso; Amanda L Zaleski; Linda S Pescatello
Journal:  Blood Press Monit       Date:  2018-08       Impact factor: 1.444

4.  Neural control of blood flow during exercise in human metabolic syndrome.

Authors:  Jacqueline K Limberg; Barbara J Morgan; Joshua J Sebranek; Lester T Proctor; Marlowe W Eldridge; William G Schrage
Journal:  Exp Physiol       Date:  2014-03-21       Impact factor: 2.969

5.  Mineralocorticoid receptor antagonists attenuate exaggerated exercise pressor reflex responses in hypertensive rats.

Authors:  Ryan M Downey; Masaki Mizuno; Jere H Mitchell; Wanpen Vongpatanasin; Scott A Smith
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-07-21       Impact factor: 4.733

6.  Exercise training improves functional sympatholysis in spontaneously hypertensive rats through a nitric oxide-dependent mechanism.

Authors:  Masaki Mizuno; Gary A Iwamoto; Wanpen Vongpatanasin; Jere H Mitchell; Scott A Smith
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-05-09       Impact factor: 4.733

7.  Elevated exercise blood pressure in middle-aged women is associated with altered left ventricular and vascular stiffness.

Authors:  Satyam Sarma; Erin Howden; Graeme Carrick-Ranson; Justin Lawley; Christopher Hearon; Mitchel Samels; Braden Everding; Sheryl Livingston; Beverley Adams-Huet; M Dean Palmer; Benjamin D Levine
Journal:  J Appl Physiol (1985)       Date:  2020-04-02

8.  PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy.

Authors:  Michael D Nelson; Florian Rader; Xiu Tang; Jane Tavyev; Stanley F Nelson; M Carrie Miceli; Robert M Elashoff; H Lee Sweeney; Ronald G Victor
Journal:  Neurology       Date:  2014-05-07       Impact factor: 9.910

9.  Differential effects of nebivolol vs. metoprolol on microvascular function in hypertensive humans.

Authors:  Alejandro Velasco; Elizabeth Solow; Angela Price; Zhongyun Wang; Debbie Arbique; Gary Arbique; Beverley Adams-Huet; Edzard Schwedhelm; Jonathan R Lindner; Wanpen Vongpatanasin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-13       Impact factor: 4.733

10.  Intrathecal fentanyl abolishes the exaggerated blood pressure response to cycling in hypertensive men.

Authors:  Thales C Barbosa; Lauro C Vianna; Igor A Fernandes; Eliza Prodel; Helena N M Rocha; Vinicius P Garcia; Natalia G Rocha; Niels H Secher; Antonio C L Nobrega
Journal:  J Physiol       Date:  2016-01-15       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.